Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Femasys Inc. - Common Stock (NQ:FEMY)

2.620 +0.070 (+2.75%)
Streaming Delayed Price Updated: 11:45 AM EDT, Sep 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Femasys Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Femasys Advances OB/GYN Expansion with Adoption of FemaSeed® Fertility Portfolio by Minnesota Women’s Care
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Partners with CapexMD to Expand Patient Access to FemaSeed® Fertility Portfolio
Collaboration provides dedicated patient financing for Femasys fertility solutions, helping reduce financial barriers to care across OB/GYN practices and fertility centers 
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Partners with UNC Health to Introduce Its FemaSeed® Fertility Portfolio Across Statewide OB/GYN Care Locations
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Announces FDA Approval of Modular PMA Submission Approach for FemBloc®
-- Modular PMA pathway advances FemBloc toward potential U.S. approval while Femasys builds commercial infrastructure across its reproductive health portfolio -- 
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Announces Financial Results for Quarter Ended June 30, 2026 and Provides Corporate Update
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Strengthens and Extends Global Patent Protection for FemBloc® with First Issued Blended Polymer Patents
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Secures $30 Million Private Placement, with Potential Proceeds of Up to $90 Million
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Regains Compliance with Nasdaq Listing Requirements
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Expands Fertility Care Portfolio in Europe with CE Mark Approval for FemHSG™ Catheter
-- New catheter complements FemVue® and supports streamlined in-office fertility evaluation -- 
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update
-- With fertility rates at historic lows, Femasys advances access to early infertility care through FemaSeed® Complete, enabling OB/GYNs to treat patients within their own practices -- 
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Enables OB/GYNs to Deliver First-Line Fertility Treatment with Initial Commercial Use of FemaSeed® Complete
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Launches FemaSeed® Complete for OB/GYNs at ACOG 2026
Expanding commercialization of first-line fertility treatment in the OB/GYN office to increase patient access 
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Drives International Growth with Israeli Market Entry for Fertility Portfolio
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Appoints John Canning as Chief Operating Officer to Drive Operational Execution and Advance Commercial Growth
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update
-- Enrollment underway in FDA-authorized FINALE pivotal trial demonstrating execution toward FemBloc® U.S. approval -- 
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Appoints Dr. Kenneth D. Eichenbaum to Board of Directors
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Advances FemBloc Toward U.S. Approval with Initiation of Pivotal Trial Enrollment
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Announces FemBloc® Permanent Birth Control Has Achieved MDSAP Certification, Advancing Global Market Access
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Receives AMA CPT Editorial Panel Approval for New Category III CPT Code for FemaSeed Intratubal Insemination
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Expands European Commercial Footprint with Swiss Partner for FemBloc, FemaSeed, and Portfolio Products
-- Multi-Product Distribution Agreement Marks Continued Commercial Momentum in Europe -- 
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Announces Partnership with Refuah Health Center to Expand First-Line Access to FemaSeed® in Community-Based Care
Partnership enables broader adoption of FemaSeed through a trusted community health provider serving a large, engaged patient population 
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic Device
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Announces Third Quarter Financial Results for 2025
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Advances Global Growth with Second Partner Order for FemBloc® in Europe
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Secures FDA Approval to Advance Final FemBloc® Trial Phase and $12 Million Financing, with Potential to Reach $58 Million
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Announces Initiation of Post-Market Surveillance Study for FemBloc® Permanent Birth Control in Europe
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys to Exhibit at the ASRM 2025 Scientific Congress & Expo
Will Showcase Latest Fertility Solutions 
From Femasys Inc.
Via GlobeNewswire
News headline image
Roadzen Inc. (NASDAQ: RDZN) Completes $7M India Financing at 100% Premium – Paves Path to Higher Valuation | More Stocks Inside
Via AB Newswire
Topics Artificial Intelligence
News headline image
Femasys Accelerates European Growth for FemBloc® with Kebomed Partnership
-- Femasys leverages Kebomed’s pan-European distribution strength to drive adoption of FemBloc permanent birth control in France and Benelux, unlocking significant market access -- 
From Femasys Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.